Articles tagged with Chemotherapy
The Texas Emerging Technology Fund has awarded a record $3.5 million to NanoMedical Systems Inc., a startup founded by Mauro Ferrari, to develop a Personalized Molecular Drug-Delivery System for controlled medicine release. The system aims to provide a safer and more reliable alternative to traditional injection methods.
The INTEREST study found oral gefitinib comparable to injected docetaxel in non-small cell lung cancer patients, with better quality of life. Common side effects included rash and diarrhoea with gefitinib, while neutropenia and asthenic disorders were more common with docetaxel.
A study found that pemetrexed-based treatment is more effective in patients with non-squamous histology than those with squamous histology, indicating improved survival benefits for some lung cancer patients.
A study found that patients with locally advanced lung cancer who received proton therapy and chemotherapy had fewer instances of bone marrow toxicity compared to those receiving IMRT and chemotherapy. This suggests that proton therapy may be a more effective option for treating this serious side effect, enabling doctors to give higher...
A study led by The University of Texas M. D. Anderson Cancer Center has found a four-drug regimen of carboplatin, paclitaxel, bevacizumab, and cetuximab to be safe for patients with advanced lung cancer. The regimen showed modest improvement in survival rate, with 53% of patients experiencing tumor shrinkage.
A phase III clinical trial found that adding bevacizumab to erlotinib therapy improves progression-free survival in advanced non-small cell lung cancer patients, but not overall survival. The combination also shows a response rate and tumor shrinkage.
A multi-center phase II clinical trial found improved survival in patients with advanced non-small cell lung cancer treated with chemotherapy and targeted therapies bevacizumab and cetuximab. The combination showed no safety concerns, indicating a potential future treatment option for lung cancer.
Dr. Gary J. Bennett's research focuses on understanding how chemotherapy drug paclitaxel causes neuropathy, a painful and debilitating side effect of cancer treatment. The $80,000 grant will support his two-year study to identify novel mechanisms and potentially lead to new therapeutic strategies.
Researchers found that dense networks of blood vessels thought to promote cancer growth may actually hinder tumor progression. Tumors fed by more normal vascular were also more vulnerable to chemotherapy drugs.
Researchers found that blocking VEGF levels in a tumor props up existing blood vessels, making them stronger and more normal. This makes the tumor more susceptible to chemotherapy drugs, offering a new strategy for cancer treatment.
Researchers have successfully treated HIV-seropositive women with assisted reproduction, achieving pregnancies and stable infant outcomes. Additionally, studies found that SC Ovidrel can be reliably used for egg-cell donation and pregnancy is possible in breast cancer patients after chemotherapy, despite reduced fertility.
Researchers at Indiana University School of Medicine report Gleevec's potential as the first effective treatment for neurofibromatosis. The anti-cancer drug has shown dramatic results in clinical tests and compassionate use cases, reducing tumor size by up to 80%.
A review found that off-label use of anticancer drugs ranged from 6.7% to 33.2% between 1990 and 2002, primarily used in palliative care. The study highlights the need for accurate data on off-label use to inform decision-making by health professionals.
Researchers have developed a novel drug delivery system that can cross the blood-brain barrier to reach and kill cancer cells in the brain. The technology has shown promise in preclinical trials, with increased survival rates and reduced tumor growth in mice and rats.
Researchers identified an 11-gene signature that separates responders from non-responders to FOLFIRI chemotherapy. The gene signature can predict treatment outcomes with 100% accuracy in a small sample size of 19 patients.
A new study published in the Proceedings of the National Academy of Sciences found that apigenin, a naturally occurring compound in fruits and vegetables, improves cancer cells' response to chemotherapy. By localizing tumor suppressor p53 in the cell nucleus, apigenin facilitates cell death and stops tumor growth.
Scientists have created a new compound that selectively kills cancer cells while sparing healthy cells, offering hope for more effective chemotherapy drugs. The compound targets cancer cells' high iron levels, delivering toxic molecules that ultimately lead to cell death.
A University of Cincinnati study finds that bisphenol A (BPA) induces proteins protecting cancer cells from chemotherapy's toxic effects. Researchers suggest BPA may be a contributing factor to chemotherapy resistance in cancer patients.
A Northwestern University research team developed a nanomaterial-based biomedical device that delivers chemotherapy drugs locally to tumor sites, reducing unnecessary exposure to toxic drugs. The device takes advantage of nanodiamonds for sustained drug release, which was demonstrated to be effective for one month.
The study found that CAPHOSOL treatment significantly limits the occurrence and severity of oral mucositis, with high levels of medication compliance and patient/physician satisfaction reported. Compliance was very high, with nearly all patients rinsing with CAPHOSOL at least once daily.
A case report describes a patient with stage IV diffuse large B-cell lymphoma (DLBCL) infiltrating the stomach, who responded well to chemotherapy. Endoscopic examination and biopsy confirmed the diagnosis, highlighting the importance of this diagnostic method for suspected gastric DLBCL.
Fluorouracil-related pneumatosis cystoides intestinalis is a newly reported case. The mechanism of this condition is unclear but may be related to altered mucosal blood flow and bowel toxicity. Researchers highlight the need for clinicians to monitor patients for potential complications during fluorouracil chemotherapy.
Multidisciplinary approaches combining chemotherapy, radiotherapy, and surgery have shown promise in treating various cancers, including lung and head and neck cancers. The addition of targeted therapies like pazopanib and cetuximab has demonstrated significant activity in reducing tumor size and improving patient outcomes.
A study at ESMO found gefitinib to be more tolerable and result in a greater likelihood of response in non-smoking Asian patients with adenocarcinoma of the lung. The targeted therapy is now considered a first-line treatment for this population.
Adding intravenous iron to chemotherapy-induced anemia treatment boosts response rates by up to 50% and reduces treatment duration, according to a new study. Lower doses of darbepoetin alfa also show improved results with the addition of iron therapy.
A phase II trial of the investigational drug pazopanib has shown promising results in treating ovarian cancer. The study found that 31% of patients experienced a significant decrease in CA-125 levels, with a median duration of response of 113 days.
A phase II trial involving 45 patients found that an alternating regimen of chemotherapy and radiotherapy, plus cetuximab, yields favorable complete response rates and long-term results comparable to the best reported in literature. However, skin toxicity and toxicities resulting in patient deaths were also observed.
Researchers found that anti-angiogenic drugs block chemotherapy-induced blood vessel formation, thereby hindering tumor regrowth. This mechanism may explain why some chemotherapy combinations enhance treatment efficacy.
Researchers discovered that injections of N-acetyl cysteine (NAC) can prevent memory loss induced by breast cancer chemotherapy drugs. The study, published in the Springer journal Metabolic Brain Disease, suggests a potential remedy for chemobrain symptoms, which affect up to 40% of cancer patients undergoing chemotherapy.
Scientists have discovered that phosphatidic acid, a phospholipid component of cellular membranes, may be a promising novel anti-cancer drug target. Researchers found that siramesine, a previously failed anxiety medication, effectively inhibits the growth of cancer cells and tumors in mice.
Researchers discovered that combining a tumor-boosting drug with radiation therapy can effectively shrink large tumors, but not small ones. The treatment works by increasing the expression of vessel proteins required for killer T cells to target the tumor.
Researchers have engineered the first drug-delivery particles capable of passing through human mucus, which could treat a range of diseases. The new system uses a polymer coating to allow drugs to penetrate mucus layers in minutes.
Grapefruit juice and other common fruit juices, such as orange and apple, can decrease the absorption of certain drugs, including those used for heart disease, cancer, and organ transplantation. This interaction may lead to a loss of beneficial effects and potentially toxic overdoses.
Researchers at Stanford University have developed a method to get around one of the most common forms of resistance, thereby opening up some resistant diseases to the reinvigorated fury of medications. The method uses an arginine-rich transporter to deliver potent medication inside a resistant cell.
Researchers at Stanford University have developed a new method using single-walled carbon nanotubes as delivery vehicles for cancer chemotherapy drugs. They found that the nanotubes can deliver up to 10 times more medication into tumor cells than traditional formulations, reducing side effects and improving treatment outcomes.
A combination of S-1 and irinotecan appears to offer a promising alternative to standard treatment for advanced non-small cell lung cancer, with similar response rates and progression-free survival. The experimental therapy resulted in less severe side effects compared to platinum-based chemotherapy regimens.
Medical physicists are developing new imaging technologies to improve breast cancer detection and treatment. Researchers have also identified ways to predict treatment success using oxygen levels within tumors, and are exploring innovative techniques such as modulated electron therapy for shallow tumor treatment.
Researchers at Cold Spring Harbor Laboratory have identified Top2A and Top1 enzymes as significant contributors to chemotherapy drug resistance. The team developed a novel screening technique to investigate the genetic basis of cancer therapy response, which could be applied widely to explore genetic mechanisms underlying drug resistance.
Researchers found that mitochondrial cholesterol increases resistance to chemotherapy in liver cancer. Statins could potentially sensitise cancer cells against chemotherapy by reducing mitochondrial cholesterol levels.
A team of researchers at Washington University in St. Louis has developed polymeric nanoparticles that can slowly release doxorubicin, a chemotherapy drug, over an extended time period. The approach aims to improve the delivery of cancer-killing drugs to pediatric brain tumors without harming healthy cells.
Researchers have discovered that a natural compound from magnolia cones can block a previously 'undruggable' pathway for cancer growth. This finding could lead to the development of new treatments by making tumors more sensitive to traditional chemotherapy drugs.
A new study from Duke University Medical Center found that changes in doctors' reimbursement for chemotherapy treatments did not affect patients' access to care. The study measured patient access by looking at distance traveled and time between diagnosis and initiation of chemotherapy.
New research indicates that the Medicare Modernization Act of 2003 has not led to significant changes in patient wait times or travel distance for chemotherapy treatment. The study found that the number of patients traveling farther for chemotherapy remained stable after 2003, with no major increases in wait times.
Researchers at UC San Diego develop a nanoscale drug delivery system targeting integrin ανβ3 protein on tumor blood vessels, reducing collateral damage. The approach shows promise in treating metastatic disease with lower chemotherapy doses.
Researchers at ESMO Conference Lugano report improved treatment outcomes for aggressive non-Hodgkin's lymphoma patients when chemotherapy is administered every 2 weeks, rather than every 3 weeks.
Researchers at McGill University have discovered a compound called silvestrol that can re-sensitize tumors to chemotherapy, making them susceptible to anticancer drugs. Silvestrol, derived from Malaysian folk medicine, has been shown to effectively reduce resistance to chemotherapy agents used to treat cancer.
A study showed that Caphosol use led to lower OM rates and severity, as well as low pain medication use and high patient satisfaction among cancer patients. High efficacy ratings were also reported by physicians.
Researchers at Ohio State University found that acute myeloid leukemia (AML) patients with mutations in the RAS gene are more likely to be cured when treated with high doses of cytarabine. Testing for RAS mutations may help doctors identify which AML patients should receive this therapy.
The study introduces HB-19, an experimental synthetic molecule that inhibits both tumor cell growth and angiogenesis. In mice models, HB-19 treatment suppresses tumor development and eliminates measurable tumors without toxicity.
A new study found that women with severe SLE who received a 6-month course of cyclophosphamide followed by mycophenolate mofetil treatment had preserved ovarian function and fertility. Disease activity was equally controlled in both groups, but patients treated with long-course CYC pulses had a higher risk of amenorrhea.
A new class of compounds, cyclopenta[b]benzofuran flavaglines, has been found to inhibit translation initiation and reverse cancer cell resistance to anticancer agents. This approach targets the eIF4A protein, which plays a central role in translation initiation.
Dan Savage, 25, survived testicular cancer at 20, gaining more confidence and starting his own art studio. He worries about losing regular medical checks after five years in remission, feeling the need for continued health monitoring.
Researchers found that solid tumor cells can adapt to chemotherapy and radiation by increasing a regulatory factor called HIF1, which drives oxygen production and growth. Blocking HIF1 may provide a clear mechanism for killing resistant tumor cells.
A pilot study at Duke University Medical Center found that disabling a protein on melanoma cells makes them more vulnerable to chemotherapy, resulting in complete responses in 8 out of 16 patients. The compound ADH-1 was tested in combination with chemotherapy and showed promising results.
Physician-scientists from NewYork-Presbyterian/Weill Cornell presented Phase II trial data showing a monoclonal antibody targeting prostate cancer cells effectively reduces PSA levels in patients with late-stage metastatic disease. The researchers also present results on RAD001, which slows cancer progression in recurrent endometrial c...
A study by Dana-Farber Cancer Institute found that chemotherapy can diminish ovarian reserve, making it harder for premenopausal breast cancer survivors to get pregnant. The research suggests that tracking breast cancer survivors' fertility after treatment is crucial.
USC researchers have identified specific genetic markers in cancer cells that predict the benefit of a novel cancer drug. The study suggests that patients with tumors exhibiting these gene expression profiles may experience increased patient benefit from the incorporation of the drug into their treatment.
Researchers reviewing randomized trials found that antioxidant supplementation may reduce overall survival in patients receiving radiotherapy. Conversely, no clear evidence suggests that antioxidant treatment increases tumor response rates during chemotherapy.
CAPHOSOL, an advanced electrolyte solution, has been shown to relieve oral mucositis and improve quality of life for cancer patients. The study found that 95% of patients reported favorable OM scores and high levels of patient and practitioner satisfaction with CAPHOSOL.
A quality-control audit found high compliance with Fox Chase Cancer Center's Partners program, which shares advanced cancer treatment guidelines with community hospitals. The study suggests that this partnership is an effective model for quickly disseminating advances in cancer treatment.